Liquidia Corporation
LQDA
Rank in Stocks
#4841
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Share Price
$34.12
Last synced: 2026-10-19
Market Cap
$3.05B
Change (1 day)
-0.67%
Change (1 year)
39.61%
Country
US
Trade Liquidia Corporation (LQDA)
Category
Healthcare
Number of shares outstanding for Liquidia Corporation (LQDA)
Number of shares outstanding as of June 2026: 88.89M
According to Liquidia Corporation latest financial reports and stock price the company's current number of shares outstanding is 88.89M. At the end of December 2023 the company had 64.99M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Liquidia Corporation (LQDA) from 2016 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 88.89M | 12.93% |
| 2024 | 78.71M | 21.10% |
| 2023 | 64.99M | 6.62% |
| 2022 | 60.96M | 22.71% |
| 2021 | 49.68M | 46.59% |
| 2020 | 33.89M | 83.35% |
| 2019 | 18.48M | 158.02% |
| 2018 | 7.16M | -16.58% |
| 2017 | 8.59M | 0.00% |
| 2016 | 8.59M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 445.06M | 400.70% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 18.05B | 20,204.85% |
HK
|
